Test Price
800 AED✅ Home Collection Available
FLT3 (ITD, D835Y) Mutation Detection in Acute Myeloid Leukemia
Executive Summary & Core Metrics
Diagnostic Precision & Service Highlights
- Diagnostic Sensitivity: 99.9% via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- Turnaround Time: Results in 3–4 business days from sample receipt.
- Clinical Support: Post-test telephonic interpretation by DHA-licensed genetics consultant.
- Insurance Billing: Direct verification via WhatsApp at +971 54 548 8731.
- Extraction Requirement: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
Test Overview & Methodology
The FLT3 (ITD, D835Y) Mutation Detection test identifies internal tandem duplications (ITD) and point mutations in the tyrosine kinase domain (D835Y) of the FLT3 gene. These mutations are critical prognostic markers in acute myeloid leukemia (AML), guiding targeted therapy decisions and risk stratification.
| Aspect | Our Testing Service | Alternative (Standard Lab) |
|---|---|---|
| Methodology | Endpoint PCR with Capillary Fragment Analysis | Conventional PCR (no fragment sizing) |
| Sensitivity | Detects mutant allele burden as low as 5% | Lower sensitivity (10–20% burden) |
| Turnaround Time | 3–4 days | 7–10 days |
| Sample Collection | Hospital extraction (bone marrow or peripheral blood) | Hospital only (if available) |
| DHA Compliance | 100% compliant with UAE health data regulations | Varies |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
"Understanding the genetic profile of your leukemia is a pivotal step toward personalized therapy. The FLT3 mutation test provides critical information that helps guide treatment decisions, but it must be interpreted in the context of complete blood counts, cytogenetics, and your overall clinical picture. I recommend discussing all results with your oncologist to build the most effective management plan."
⚠️ Do not discontinue or modify your prescribed medication without consulting your doctor.
Advisory: Medication and Treatment Continuity
Do not discontinue or modify any prescribed medications without consulting your treating physician. The FLT3 test is a diagnostic aid and does not replace ongoing clinical management.
Safety Exclusions & Emergency Guidance
- Bone Marrow Aspiration Exclusion: Platelet count < 50,000/μL, INR > 1.5, or existing bleeding disorder. Peripheral blood draw may be used as an alternative if clinically indicated.
- Cold-Chain Transport: Samples must be transported at 2–8°C. Hospital phlebotomy teams ensure compliance.
- Emergency Red Flags: If you experience new fever > 38.5°C, active bleeding, or sudden neurological changes, attend the nearest emergency room before proceeding with sample collection.
Patient FAQ & Clinical Guidance
1. What is the purpose of the FLT3 mutation test?
This test detects two types of mutations in the FLT3 gene—internal tandem duplications (ITD) and D835Y point mutations—which help classify the risk level of acute myeloid leukemia and guide targeted therapy, such as FLT3 inhibitors.
2. How is the sample collected?
The sample is collected by a healthcare professional in a hospital setting. For bone marrow aspiration, local anesthesia is used to minimize discomfort. The procedure is brief, and sample integrity is maintained through proper cold-chain handling.
3. Do I need a prescription?
Yes, a valid prescription from your physician is required. You can send your prescription for verification via WhatsApp at +971 54 548 8731. Exceptions apply for pre-surgical clearance or travel requirements.
4. When will I receive my results?
Results are typically available within 3–4 business days from sample receipt. You will receive a secure PDF report, and our genetics consultant can schedule a telephonic discussion to explain the findings.
UAE Regulatory & Data Privacy Adherence
Compliance Framework
- Data Protection: All patient data processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Information Technology: Compliant with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Medical Liability: Patient safety and consent governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Accreditation: ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139).
- DHA License: Facility No. 1143.
Clinical & Logistical Metadata
| Test Name | FLT3 (ITD, D835Y) Mutation Detection |
| Price (AED) | 800 AED |
| Turnaround Time | 3–4 business days |
| Sample Type / Matrix | Peripheral Blood or Bone Marrow Aspirate (Hospital Extraction Only) |
| Methodology Used | Endpoint PCR with Capillary Fragment Analysis |
| ICD-10-CM Code | C92.0 (Acute myeloblastic leukemia) |
| LOINC Code | 21718-3 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians